The Subcutaneous Defibrillator

The recently commercially available subcutaneous implantable cardioverter-defibrillator (S-ICD) uses a completely subcutaneous electrode configuration to treat potentially lethal ventricular tachyarrhythmia. Clinical trials have proven its effectiveness in detecting and treating ventricular fibrilla...

Full description

Saved in:
Bibliographic Details
Published in:Journal of the American College of Cardiology 2014-04, Vol.63 (15), p.1473-1479
Main Authors: Aziz, Sally, Leon, Angel R., MD, El-Chami, Mikhael F., MD
Format: Article
Language:English
Subjects:
Cardiac arrhythmia
Cardiology
Cardiovascular
Defibrillators
Electrodes
FDA approval
Infections
Internal Medicine
Migration
Mortality
Ostomy
Patients
subcutaneous ICD
sudden cardiac death
transvenous ICD
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The recently commercially available subcutaneous implantable cardioverter-defibrillator (S-ICD) uses a completely subcutaneous electrode configuration to treat potentially lethal ventricular tachyarrhythmia. Clinical trials have proven its effectiveness in detecting and treating ventricular fibrillation and tachycardia. The S-ICD offers the advantage of eliminating the need for intravenous and intracardiac leads and their associated risks and shortcomings. However, its major disadvantage is its inability to provide bradycardia rate support and antitachycardia pacing to terminate ventricular tachycardia. This paper discusses the S-ICD clinical trials and advantages and disadvantages of this novel technology to help the physician identify its role and select candidate patients who will benefit from this device.
ISSN:0735-1097
1558-3597
DOI:10.1016/j.jacc.2014.01.018